Financial Gravity Asset Management, Inc. Crispr Therapeutics Ag Transaction History

Financial Gravity Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$60.67 - $89.12 $9,161 - $13,457	-151 Reduced 96.79%	5 $312,000
Q3 2023 Nov 15, 2023	BUY	$45.39 - $59.0 $4,539 - $5,900	100 Added 178.57%	156 $7,000
Q2 2023 Aug 08, 2023	BUY	$43.47 - $67.77 $2,434 - $3,795	56 New	56 $387,000
Q4 2022 Feb 15, 2023	SELL	$39.19 - $65.67 $41,698 - $69,872	-1,064 Reduced 96.29%	41 $394,000
Q3 2022 Nov 03, 2022	BUY	$61.1 - $83.78 $67,515 - $92,576	1,105 New	1,105 $3.51 Million
Q2 2022 Aug 05, 2022	SELL	$43.23 - $73.83 $2,723 - $4,651	-63 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$53.19 - $79.24 $691 - $1,030	-13 Reduced 17.11%	63 $4,000
Q4 2021 Feb 11, 2022	BUY	$70.09 - $111.29 $5,326 - $8,458	76 New	76 $6,000
Q3 2021 Nov 12, 2021	BUY	$110.2 - $156.64 $0 - $0	0 New	0 $112,000

485

57.5M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.12B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.